Message from the president

Takara Bio Inc. began as the biomedical business unit of Takara Shuzo Co., Ltd. (now Takara Holdings Inc.).

  Based on the Company's mission - Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy - Takara Bio will focus on two business segments that utilize its core biotechnology and encourage broader expansion: the Bioindustry Business, the basis for stable earning providing research reagents, scientific instruments, and various contracted services to life science researchers at universities and companies worldwide; the Gene Therapy Business, the segment that the Company views as the foundation for future growth developing and commercializing gene therapies for cancer, and so on.

  Amid improving the business environment such as technology development and amendment to regulatory laws for the fields of regenerative medicine, Takara Bio will accelerate the development of new products in the fields, such as basic research utilizing stem cells and regenerative medicine and cell therapy research. Leveraging the technologies and expertise developed over the years in gene therapy and clinical development, Takara Bio aims to expand its CDMO (Contract Development and Manufacturing Organization) business by providing contracted services including GMP (Good Manufacturing Practice) production of regenerative products, and serving as a contracted partner for R&D in the core facility of the Center for Gene and Cell Processing in Kusatsu city, Shiga prefecture.

  We deeply appreciate your ongoing support.

   Koichi Nakao

return to top

Our website uses cookies to ensure that we give you the best user experience.Read more
By continuing to use our site, you consent to our cookies.